About PROMETHERA® Biosciences
Promethera® Biosciences is a Belgian pharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatment based on allogeneic adult stem cell technology.
Promethera® Biosciences' mission is to discover, develop, and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells harvested from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type, the Heterologous Human Adult Liver Progenitor Cell (HHALPC):
- Promethera® HepaStem, a unique cell therapy product, to treat severe diseases of the liver affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver diseases that can be addressed with the same product.
- Promethera® H2Screen and H3Screen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of new drugs by the human liver. The cell model is designed for the discovery and pre-clinical evaluation of new chemical entities.
Promethera® Biosciences was founded in 2009 based on research discovery by Professor Etienne Sokal's team (UCL, Brussels). Prof Sokal is a leading expert in hepatology and cell therapy. Eric Halioua is the Chief Executive Officer and co-founder of Promethera® Biosciences.
The name of the Company was derived from the term "PROgenitor MEdicinal THERApies".
Promethera® Biosciences has been funded by Venture Capital and grant and loans from the Walloon region (Belgium) since 2009 and a total of 65.5M Euros has been invested through three rounds of financing.
As of August 2012, Promethera® Biosciences is constituted of a motivated team of 44 employees and governed by a seasoned management board.
PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01